Recent Updates
Recently added Catalysts
CGC

CANOPY GROWTH REPORTS FOURTH QUARTER AND FISCAL YEAR 2021 FINANCIAL RESULTS Achieves 37% revenue growth in FY 2021 with strong double-digit growth across both cannabis and other consumer products businesses Improved supp

Key Takeaway: CANOPY GROWTH REPORTS FOURTH QUARTER AND FISCAL YEAR 2021 FINANCIAL RESULTS Achieves 37% revenue growth in FY 2021 with strong double-digit growth across both cannabis and other consumer products businesses Improved supply chain execution and quality enhancements are leading to

Full Press Release Details

CANOPY GROWTH REPORTS FOURTH QUARTER AND FISCAL YEAR 2021 FINANCIAL RESULTS
Achieves 37% revenue growth in FY 2021 with strong double-digit growth across both cannabis and other consumer products businesses
Improved supply chain execution and quality enhancements are leading to commercial success
Maintains #1 market share1 of the total flower category in Canada; recently announced acquisitions further solidify Canopy's leadership position in the Canadian recreational market
The U.S. ecosystem strategy continues to gain traction with focus to further capitalize on growth opportunities in the U.S.
Remains on track to achieve positive Adjusted EBITDA during the second half of FY 2022
SMITHS FALLS, ON - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED, NASDAQ:CGC) today announces its financial results for the fourth quarter and Fiscal Year 2021 ended March 31, 2021. All financial information in this press release is reported in Canadian dollars, unless otherwise indicated.
"During Fiscal 2021, Canopy Growth transformed into a CPG-modelled organization, reinforcing a foundation for sustained growth and long-term success. By leveraging consumer insights and innovation to deliver best-in-class products, Canopy Growth is positioned to achieve our goal of unleashing the power of cannabis to improve lives," said David Klein, CEO, Canopy Growth. "We are starting to see strong momentum across all of our key businesses and remain firmly focused on capitalizing on U.S. opportunities in Fiscal 2022."
"We made tremendous progress improving our supply chain and right-sizing our manufacturing footprint, bringing supply and demand into balance," added Mike Lee, CFO. "Our cost savings program is on track to deliver $150-$200 million of savings within the next 18 months, and we remain committed to our path to profitability by the end of Fiscal 2022, while continuing to invest in an organization that is focused on insights, innovation and gaining momentum in the U.S. market."
Fourth Quarter Fiscal 2021 Financial Summary
(in millions of Canadian dollars, unaudited) Net revenue Gross margin percentage Adjusted gross margin percentage 2 Net loss Adjusted EBITDA 3 Free cash flow 4
Reported $148.4 7% 14% $(616.7) $(94.0) $(124.4)
vs. Q4 2020 38% NM (2,800) bps 54% 8% 59%
Fiscal Year 2021 Financial Summary
(in millions of Canadian dollars, unaudited) Net revenue Gross margin percentage Adjusted gross margin percentage 5 Net loss Adjusted EBITDA Free cash flow
Reported $546.6 12% 17% $(1,670.8) $(340.3) $(630.2)
vs. Fiscal 2020 37% 2,000 bps (900 bps) (20%) 23% 57%
Fourth Quarter and Full Year Fiscal 2021 Corporate Financial Highlights
Fourth Quarter and Fiscal Year 2021 Business & Operational Highlights
Fourth Quarter and Fiscal Year 2021 Financial and Operational Review
(in millions of Canadian dollars, unaudited) Q4 2021 Q4 2020 vs. Q4 2020 FY2021 FY2020 vs. FY2020
Canadian recreational cannabis net revenue
- Business to business 6 $43.3 $30.9 40% $163.6 $121.6 35%
- Business to consumer $17.8 $13.0 37% $66.0 $52.1 27%
$61.1 $43.9 39% $229.6 $173.7 32%
Canadian medical cannabis net revenue 7 $13.7 $13.6 1% $55.5 $51.6 8%
$74.8 $57.5 30% $285.1 $225.3 27%
International and other revenue
- C 3 $15.8 $16.2 (2%) $62.3 $53.8 16%
- Other $10.7 $5.8 84% $31.3 $15.8 98%
$26.5 $22.0 20% $93.6 $69.6 34%
Global cannabis net revenue $101.3 $79.5 27% $378.7 $294.9 28%
Other consumer products
- Storz & Bickel $17.9 $11.8 52% $81.0 $48.4 67%
- This Works $8.5 $8.3 2% $33.3 $24.7 35%
- Other $20.7 $8.3 149% $53.6 $30.8 74%
Other consumer products revenue $47.1 $28.4 66% $167.9 $103.9 62%
Net revenue $148.4 $107.9 38% $546.6 $398.8 37%
This table has been recast to align with our new segment reporting. International and other revenue includes revenue from our international medical business and hemp-derived CBD business. Other consumer products includes revenue from Storz & Bickel, This Works, BioSteel, clinics, accessories and other ancillary businesses.
(in millions of Canadian dollars, unaudited) Q4 2021 Q4 2020 vs. Q4 2020 FY2021 FY2020 vs. FY2020
Canadian recreational cannabis
- Dry bud 8 $67.9 $48.8 39% $238.0 $238.1 -
- Oils and softgels 8 $6.7 $5.2 29% $28.8 $21.6 33%
- Beverages, edibles, topicals and vapes $7.1 $1.1 NM $31.7 $1.1 NM
- Other revenue adjustments 9 $(3.1) $(5.4) 43% $(14.0) $(51.5) 73%
- Excise taxes $(17.5) $(5.8) (202%) $(54.9) $(35.6) (54%)
$61.1 $43.9 39% $229.6 $173.7 32%
Medical cannabis and other
- Dry bud $9.7 $11.1 (13%) $40.5 $37.4 8%
- Oils and softgels $25.5 $25.8 (1%) $101.9 $89.0 14%
- Beverages, edibles, topicals and vapes $6.4 $- NM $12.3 $- NM
- Excise taxes $(1.4) $(1.3) (8%) $(5.6) $(5.2) (8%)
$40.2 $35.6 13% $149.1 $121.2 23%
Global cannabis net revenue $101.3 $79.5 27% $378.7 $294.9 28%
Other consumer products
- Storz & Bickel $17.9 $11.8 52% $81.0 $48.4 67%
- This Works $8.5 $8.3 2% $33.3 $24.7 35%
- Other $20.7 $8.3 149% $53.6 $30.8 74%
Other consumer products revenue $47.1 $28.4 66% $167.9 $103.9 62%
Net revenue $148.4 $107.9 38% $546.6 $398.8 37%
This table has been recast to align with our new segment reporting.
International Cannabis
Other Consumer Products
Subsequent to Quarter-end
The fourth quarter fiscal 2021, fourth quarter fiscal 2020, fiscal year 2021 and fiscal year 2020 financial results presented in this press release have been prepared in accordance with U.S. GAAP.
Webcast and Conference Call Information
The Company will host a conference call and audio webcast with David Klein, CEO and Mike Lee, CFO at 10:00 AM Eastern Time on June 1, 2021.
A live audio webcast will be available at:
A replay will be accessible by webcast until 11:59 PM ET on August 30, 2021 at:
Adjusted EBITDA is a non-GAAP measure used by management that is not defined by U.S. GAAP and may not be comparable to similar measures presented by other companies. Adjusted EBITDA is calculated as the reported net loss, adjusted to exclude income tax recovery (expense); other income (expense), net; loss on equity method investments; share-based compensation expense; depreciation and amortization expense; asset impairment and restructuring costs; expected credit losses on financial assets and related charges; restructuring and other charges recorded in cost of goods sold; and charges related to the flow-through of inventory step-up on business combinations, and further adjusted to remove acquisition-related costs. The Adjusted EBITDA reconciliation is
presented within this news release and explained in the Company's Annual Report on Form 10-K to be filed with the SEC.
Free Cash Flow is a non- GAAP measure used by management that is not defined by U.S. GAAP and may not be comparable to similar measures presented by other companies. This measure is calculated as net cash provided by (used in) operating activities less purchases of and deposits on property, plant and equipment. The Free Cash Flow reconciliation is presented within this news release and explained in the Company's Annual Report on Form 10-K to be filed with the SEC.
Adjusted Gross Margin and Adjusted Gross Margin Percentage are non-GAAP measures used by management that are not defined by U.S. GAAP and may not be comparable to similar measures presented by other companies. Adjusted Gross Margin is calculated as gross margin excluding restructuring and other charges recorded in cost of goods sold, and charges related to the flow-through of inventory step-up on business combinations. Adjusted Gross Margin Percentage is calculated as Adjusted Gross Margin divided by net revenue. The Adjusted Gross Margin and Adjusted Gross Margin Percentage reconciliation is presented within this news release.
Vice President, Investor Relations & Competitive Intelligence
Director, Investor Relations
About Canopy Growth Corporation
Canopy Growth (TSX:WEED,NASDAQ:CGC ) is a world-leading diversified cannabis and cannabinoid-based consumer product company, driven by a passion to improve lives, end prohibition, and strengthen communities by unleashing the full potential of cannabis. Leveraging consumer insights and innovation, we offer product varieties in high quality dried flower, oil, softgel capsule, infused beverage, edible, and topical formats, as well as vaporizer devices by Canopy Growth and industry-leader Storz & Bickel. Our global medical brand, Spectrum Therapeutics, sells a range of full-spectrum products using its colour-coded classification system and is a market leader in both Canada and Germany. Through our award-winning Tweed and Tokyo Smoke banners, we reach our adult-use consumers and have built a loyal following by focusing on top quality products and meaningful customer relationships. Canopy Growth has entered into the health and wellness consumer space in key markets including Canada, the United States, and Europe through BioSteel sports nutrition, and This Works skin and sleep solutions; and has introduced additional federally-permissible CBD products to the United States through our First & Free and Martha Stewart CBD brands. Canopy Growth has an established partnership with Fortune 500 alcohol leader Constellation Brands. For more information visit www.canopygrowth.com.
Notice Regarding Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of applicable securities laws, which involve certain known and unknown risks and uncertainties. Forward-looking statements predict or describe our future operations, business plans, business and investment strategies and the performance of our investments. These forward-looking statements are generally identified by their use of such terms and phrases as "intend," "goal," "strategy," "estimate," "expect," "project," "projections," "forecasts," "plans," "seeks," "anticipates," "potential," "proposed," "will," "should," "could," "would," "may," "likely," "designed to," "foreseeable future," "believe," "scheduled" and other similar expressions. Our actual results or outcomes may differ materially from those anticipated. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statement was made.
Forward-looking statements include, but are not limited to, statements with respect to:
Certain of the forward-looking statements contained herein concerning the industries in which we conduct our business are based on estimates prepared by us using data from publicly available governmental sources, market research, industry analysis and on assumptions based on data and knowledge of these industries, which we believe to be reasonable. However, although generally indicative of relative market positions, market shares and performance characteristics, such data is inherently imprecise. The industries in which we conduct our business involve risks and uncertainties that are subject to change based on various factors, which are described further below.
The forward-looking statements contained herein are based upon certain material assumptions that were applied in drawing a conclusion or making a forecast or projection, including: (i) management's perceptions of historical trends, current conditions and expected future developments; (ii) our ability to generate cash flow from operations; (iii) general economic, financial market, regulatory and political conditions in which we operate; (iv) the production and manufacturing capabilities and output from our facilities and our joint ventures, strategic alliances and equity investments; (v) consumer interest in our products; (vi) competition; (vii) anticipated and unanticipated costs; (viii) government regulation of our activities and products including but not limited to the areas of taxation and environmental protection; (ix) the timely receipt of any required regulatory authorizations, approvals, consents, permits and/or licenses; (x) our ability to obtain qualified staff, equipment and services in a timely and cost-efficient manner; (xi) our ability to conduct operations in a safe, efficient and effective manner; (xii) our ability to realize anticipated benefits, synergies or generate revenue, profits or value from our recent acquisitions into our existing operations; (xiii) our ability to continue to operate in light of the COVID-19 pandemic and the impact of the pandemic on demand for, and sales of, our products and our distribution channels; and (xiv) other considerations that management believes to be appropriate in the circumstances. While our management considers these assumptions to be reasonable based on information currently available to management, there is no assurance that such expectations will prove to be correct.
By their nature, forward-looking statements are subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking statements in this press release
and other reports we file with, or furnish to, the Securities and Exchange Commission (the "SEC") and other regulatory agencies and made by our directors, officers, other employees and other persons authorized to speak on our behalf. Such factors include, without limitation, changes in laws, regulations and guidelines and our compliance with such laws, regulations and guidelines; the risk that the COVID-19 pandemic may disrupt our operations and those of our suppliers and distribution channels and negatively impact the demand for and use of our products; consumer demand for cannabis and U.S. hemp products; our limited operating history; the risks and uncertainty regarding future product development; our reliance on licenses issued by and contractual arrangements with various federal, state and provincial governmental authorities; the risk that cost savings and any other synergies from the CBI Group Investments may not be fully realized or may take longer to realize than expected; risks associated with jointly owned investments; risks relating to our current and future operations in emerging markets; future levels of revenues and the impact of increasing levels of competition; risks related to the protection and enforcement of our intellectual property rights; our ability to manage disruptions in credit markets or changes to our credit ratings; future levels of capital, environmental or maintenance expenditures, general and administrative and other expenses; the success or timing of completion of ongoing or anticipated capital or maintenance projects; business strategies, growth opportunities and expected investment; the adequacy of our capital resources and liquidity, including but not limited to, availability of sufficient cash flow to execute our business plan (either within the expected timeframe or at all); counterparty risks and liquidity risks that may impact our ability to obtain loans and other credit facilities on favorable terms; the potential effects of judicial, regulatory or other proceedings, or threatened litigation or proceedings, on our business, financial condition, results of operations and cash flows; risks related to stock exchange restrictions; risks associated with divestment and restructuring; volatility in and/or degradation of general economic, market, industry or business conditions; our exposure to risks related to an agricultural business, including wholesale price volatility and variable product quality; third-party transportation risks; compliance with applicable environmental, economic, health and safety, energy and other policies and regulations and in particular health concerns with respect to vaping and the use of cannabis and U.S. hemp products in vaping devices; the anticipated effects of actions of third parties such as competitors, activist investors or federal, state, provincial, territorial or local regulatory authorities, or self-regulatory organizations; changes in regulatory requirements in relation to our business and products; and the factors discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2021. Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking statements.
Forward-looking statements are provided for the purposes of assisting the reader in understanding our financial performance, financial position and cash flows as of and for periods ended on certain dates and to present information about management's current expectations and plans relating to the future, and the reader is cautioned that the forward-looking statements may not be appropriate for any other purpose. While we believe that the assumptions and expectations reflected in the forward-looking statements are reasonable based on information currently available to management, there is no assurance that such assumptions and expectations will prove to have been correct. Forward-looking statements are made as of the date they are made and are based on the beliefs, estimates, expectations and opinions of management on that date. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking statements, except as required by law. The forward-looking statements contained in this press release and other reports we file with, or furnish to, the SEC and other regulatory agencies and made by our directors, officers, other employees and other persons authorized to speak on our behalf are expressly qualified in their entirety by these cautionary statements.
CANOPY GROWTH CORPORATION CONSOLIDATED BALANCE SHEETS (in thousands of Canadian dollars, except number of shares and per share data, unaudited)
March 31, 2021 March 31, 2020
ASSETS
Current assets:
Cash and cash equivalents $1,154,653 $1,303,176
Short-term investments 1,144,563 673,323
Restricted short-term investments 11,332 21,539
Amounts receivable, net 92,435 90,155
Inventory 367,979 391,086
Prepaid expenses and other assets 67,232 85,094
Total current assets 2,838,194 2,564,373
Equity method investments 100 65,843
Other financial assets 708,167 249,253
Property, plant and equipment 1,074,537 1,524,803
Intangible assets 308,167 476,366
Goodwill 1,889,354 1,954,471
Other assets 4,961 22,636
Total assets $6,823,480 $6,857,745
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable $67,262 $123,393
Other accrued expenses and liabilities 100,813 64,994
Current portion of long-term debt 9,827 16,393
Other liabilities 106,428 215,809
Total current liabilities 284,330 420,589
Long-term debt 1,573,136 449,022
Deferred income tax liabilities 21,379 47,113
Liability arising from Acreage Arrangement 600,000 250,000
Warrant derivative liability 615,575 322,491
Other liabilities 107,240 190,660
Total liabilities 3,201,660 1,679,875
Commitments and contingencies (Note 34)
Redeemable noncontrolling interest 135,300 69,750
Canopy Growth Corporation shareholders' equity:
Common shares - $nil par value; Authorized - unlimited number of shares; Issued - 382,875,179 shares and 350,112,927 shares, respectively 7,168,557 6,373,544
Additional paid-in capital 2,415,650 2,615,155
Accumulated other comprehensive (loss) income (34,240) 220,899
Deficit (6,068,156) (4,323,236)
Total Canopy Growth Corporation shareholders' equity 3,481,811 4,886,362
Noncontrolling interests 4,709 221,758
Total shareholders' equity 3,486,520 5,108,120
Total liabilities and shareholders' equity $6,823,480 $6,857,745
CANOPY GROWTH CORPORATION CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands of Canadian dollars, except number of shares and per share data, unaudited)
Three months ended March 31,
2021 2020
Revenue $167,375 $115,068
Excise taxes 18,936 7,155
Net revenue 148,439 107,913
Cost of goods sold 138,639 199,738
Gross margin 9,800 (91,825)
Operating expenses:
Selling, general and administrative expenses 148,666 197,579
Share-based compensation 18,517 78,354
Expected credit losses on financial assets and related charges 1,000 -
Asset impairment and restructuring costs 74,819 623,266
Total operating expenses 243,002 899,199
Operating loss (233,202) (991,024)
Loss from equity method investments (11,778) (57,752)
Other income (expense), net (366,770) (376,295)
Loss before income taxes (611,750) (1,425,071)
Income tax (expense) recovery (4,945) 98,666
Net loss (616,695) (1,326,405)
Net income (loss) attributable to noncontrolling interests and redeemable noncontrolling interest 83,283 (23,384)
Net loss attributable to Canopy Growth Corporation $(699,978) $(1,303,021)
Basic and diluted loss per share $(1.85) $(3.72)
Basic and diluted weighted average common shares outstanding 378,519,753 349,837,102
CANOPY GROWTH CORPORATION CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands of Canadian dollars, except number of shares and per share data, unaudited)
Years ended March 31,
2021 2020
Revenue $607,198 $439,626
Excise taxes 60,549 40,854
Net revenue 546,649 398,772
Cost of goods sold 479,689 430,456
Gross margin 66,960 (31,684)
Operating expenses:
Selling, general and administrative expenses 575,389 693,737
Share-based compensation 91,149 320,276
Expected credit losses on financial assets and related charges 109,480 -
Asset impairment and restructuring costs 534,398 623,266
Total operating expenses 1,310,416 1,637,279
Operating loss (1,243,456) (1,668,963)
Loss from equity method investments (52,629) (64,420)
Other income (expense), net (387,876) 224,329
Loss before income taxes (1,683,961) (1,509,054)
Income tax recovery 13,141 121,614
Net loss (1,670,820) (1,387,440)
Net income (loss) attributable to noncontrolling interests and redeemable noncontrolling interest 74,100 (66,114)
Net loss attributable to Canopy Growth Corporation $(1,744,920) $(1,321,326)
Basic and diluted loss per share $(4.69) $(3.80)
Basic and diluted weighted average common shares outstanding 371,662,296 348,038,163
CANOPY GROWTH CORPORATION CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands of Canadian dollars, unaudited)
Years ended March 31,
2021 2020
Cash flows from operating activities:
Net loss $(1,670,820) $(1,387,440)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of property, plant and equipment 70,914 73,716
Amortization of intangible assets 56,204 51,297
Share of loss on equity method investments 52,629 64,420
Share-based compensation 91,149 320,276
Asset impairment and restructuring costs 534,398 623,266
Expected credit losses on financial assets and related charges 109,480 -
Income tax recovery (13,141) (121,614)
Non-cash foreign currency 8,138 (2,012)
Interest paid (25,649) (25,472)
Change in operating assets and liabilities, net of effects from purchases of businesses:
Amounts receivable (11,994) 20,979
Prepaid expenses and other assets 77 (26,917)
Inventory 17,211 (177,091)
Accounts payable and accrued liabilities (9,627) (20,750)
Other, including non-cash fair value adjustments 325,302 (165,293)
Net cash used in operating activities (465,729) (772,635)
Cash flows from investing activities:
Purchases of and deposits on property, plant and equipment (164,502) (704,944)
Purchases of intangible assets (9,639) (16,957)
Proceeds on sale of property, plant and equipment 45,921 -
Proceeds on sale of intangible assets 18,337 -
(Purchases) redemption of short-term investments (459,834) 1,427,482
Cash outflow on completion of RIV Arrangement (152,801) -
Sale of (investments in) equity method investments 7,000 (5,135)
Investments in other financial assets (44,721) (129,590)
Investment in Acreage Arrangement (49,849) (395,190)
Loan advanced to Acreage Hempco (66,995) -
Recovery of amounts related to construction financing 10,000 -
Payment of acquisition related liabilities (16,897) (24,482)
Net cash outflow on acquisition of noncontrolling interests (125) -
Net cash outflow on acquisition of subsidiaries - (498,838)
Net cash used in investing activities (884,105) (347,654)
Cash flows from financing activities:
Payment of share issue costs (131) -
Proceeds from issuance of shares by RIV Capital 1,380 1,172
Proceeds from exercise of stock options 156,897 41,413
Proceeds from exercise of warrants 245,186 446
Issuance of long-term debt 893,160 14,761
Payment of debt issue costs (16,104) -
Repayment of long-term debt (15,619) (114,953)
Net cash provided by (used in) financing activities 1,264,769 (57,161)
Effect of exchange rate changes on cash and cash equivalents (63,458) (204)
Net decrease in cash and cash equivalents (148,523) (1,177,654)
Cash and cash equivalents, beginning of period 1,303,176 2,480,830
Cash and cash equivalents, end of period $1,154,653 $1,303,176
Adjusted Gross Margin 1 Reconciliation (Non-GAAP Measure)
Three months ended March 31,
(in thousands of Canadian dollars except where indicated; unaudited) 2021 2020
Net revenue $148,439 $107,913
Gross margin, as reported 9,800 (91,825)
Adjustments to gross margin:
Restructuring and other charges recorded in cost of goods sold 10,348 132,089
Charges related to the flow-through of inventory step-up on business combinations - 4,687
Adjusted gross margin 1 $20,148 $44,951
Adjusted gross margin percentage 1 14% 42%
Years ended March 31,
(in thousands of Canadian dollars, unaudited) 2021 2020
Net revenue $546,649 $398,772
Gross margin, as reported 66,960 (31,684)
Adjustments to gross margin:
Restructuring and other charges recorded in cost of goods sold 25,985 132,089
Charges related to the flow-through of inventory step-up on business combinations 1,494 4,687
Adjusted gross margin 1 $94,439 $105,092
Adjusted gross margin percentage 1 17% 26%
1 Adjusted gross margin and adjusted gross margin percentage are non-GAAP measures. See "Non-GAAP Measures".
Adjusted EBITDA 1 Reconciliation (Non-GAAP Measure)
Three months ended March 31,
(in thousands of Canadian dollars, unaudited) 2021 2020
Net loss $(616,695) $(1,326,405)
Income tax expense (recovery) 4,945 (98,666)
Other (income) expense, net 366,770 376,295
Loss on equity method investments 11,778 57,752
Share-based compensation 2 18,517 78,354
Acquisition-related costs 5,561 1,840
Depreciation and amortization 2 28,928 48,781
Asset impairment and restructuring costs 74,819 623,266
Expected credit losses on financial assets and related charges 1,000 -
Restructuring and other charges recorded in cost of goods sold 10,348 132,089
Charges related to the flow-through of inventory step-up on business combinations - 4,687
Adjusted EBITDA 1 $(94,029) $(102,007)
Years ended March 31,
(in thousands of Canadian dollars, unaudited) 2021 2020
Net loss $(1,670,820) $(1,387,440)
Income tax recovery (13,141) (121,614)
Other (income) expense, net 387,876 (224,329)
Loss on equity method investments 52,629 64,420
Share-based compensation 2 91,149 320,276
Acquisition-related costs 13,522 20,840
Depreciation and amortization 2 127,118 125,013
Asset impairment and restructuring costs 534,398 623,266
Expected credit losses on financial assets and related charges 109,480 -
Restructuring and other charges recorded in cost of goods sold 25,985 132,089
Charges related to the flow-through of inventory step-up on business combinations 1,494 4,687
Adjusted EBITDA 1 $(340,310) $(442,792)
1 Adjusted EBITDA is a non-GAAP measure. See "Non-GAAP Measures".
2 From Consolidated Statements of Cash Flows.
Free Cash Flow 1 Reconciliation (Non-GAAP Measure)
Three months ended March 31,
(in thousands of Canadian dollars, unaudited) 2021 2020
Net cash used in operating activities $(97,830) $(210,639)
Purchases of and deposits on property, plant and equipment (26,525) (94,086)
Free cash flow 1 $(124,355) $(304,725)
Years ended March 31,
(in thousands of Canadian dollars, unaudited) 2021 2020
Net cash used in operating activities $(465,729) $(772,635)
Purchases of and deposits on property, plant and equipment (164,502) (704,944)
Free cash flow 1 $(630,231) $(1,477,579)
1 Free cash flow is a non-GAAP measure. See "Non-GAAP Measures".
Segmented Revenue by Channel Three months ended
(in thousands of Canadian dollars, unaudited) December 31, 2020 September 30, 2020 June 30, 2020
Canadian recreational cannabis net revenue
Business-to-business 1 $43,129 $42,223 $34,934
Business-to-consumer 20,224 18,709 9,330
63,353 60,932 44,264
Canadian medical cannabis net revenue 2 13,947 13,888 13,910
77,300 74,820 58,174
International and other revenue
C 3 17,642 13,556 15,369
Other 8,886 5,918 5,739
26,528 19,474 21,108
Global cannabis net revenue 103,828 94,294 79,282
Other consumer products
Storz & Bickel 24,147 21,836 17,120
This Works 10,907 7,833 6,049
Other 13,646 11,303 7,965
Other consumer products revenue 48,700 40,972 31,134
Net revenue $152,528 $135,266 $110,416
1 Reflects excise taxes of $15,977 and other revenue adjustments, representing our determination of returns and pricing adjustments, of $3,750 for the three months ended December 31, 2020; excise taxes of $14,200 and other revenue adjustments of $3,750 for the three months ended September 30, 2020; and excise taxes of $7,246 and other revenue adjustments of $3,400 for the three months ended June 30, 2020.
2 Reflects excise taxes of $1,402 for the three months ended December 31, 2020; $1,362 for the three months ended September 30, 2020; and $1,426 for the three months ended June 30, 2020.
Segmented Revenue by Form Three months ended
(in thousands of Canadian dollars, unaudited) December 31, 2020 September 30, 2020 June 30, 2020
Canadian recreational cannabis
Dry bud 1 $66,210 $63,895 $40,129
Oils and softgels 1 7,292 7,021 7,721
Beverages, edibles, topicals and vapes 9,578 7,966 7,060
Other revenue adjustments (3,750) (3,750) (3,400)
Excise taxes (15,977) (14,200) (7,246)
63,353 60,932 44,264
Medical cannabis and other
Dry bud 10,098 9,836 10,832
Oils and softgels 27,696 23,458 25,215
Beverages, edibles, topicals and vapes 4,083 1,430 397
Excise taxes (1,402) (1,362) (1,426)
40,475 33,362 35,018
Global cannabis net revenue 103,828 94,294 79,282
Other consumer products
Storz & Bickel 24,147 21,836 17,120
This Works 10,907 7,833 6,049
Other 13,646 11,303 7,965
Other consumer products revenue 48,700 40,972 31,134
Net revenue $152,528 $135,266 $110,416
1 Excludes the impact of other revenue adjustments.
Schedule 10 - Segmented Gross Margin Reconciliation
Three months ended
(in thousands of Canadian dollars except where indicated; unaudited) December 31, 2020 September 30, 2020 June 30, 2020
Global cannabis segment
Net revenue $103,828 $94,294 $79,282
Cost of goods sold 96,434 82,232 86,140
Gross margin 7,394 12,062 (6,858)
Gross margin percentage 7% 13% (9%)
Other consumer products segment
Revenue $48,700 $40,972 $31,134
Cost of goods sold 31,509 26,954 17,781
Gross margin 17,191 14,018 13,353
Gross margin percentage 35% 34% 43%
Schedule 11 - Segmented Adjusted Gross Margin Reconciliation (Non-GAAP Measure)
Three months ended
(in thousands of Canadian dollars except where indicated; unaudited) December 31, 2020 September 30, 2020 June 30, 2020
Global cannabis segment
Net revenue $103,828 $94,294 $79,282
Gross margin, as reported 7,394 12,062 (6,858)
Adjustments to gross margin:
Restructuring and other charges recorded in cost of goods sold 15,637 - -
Adjusted gross margin 1 $23,031 $12,062 $(6,858)
Adjusted gross margin percentage 1 22% 13% (9%)
Other consumer products segment
Revenue $48,700 $40,972 $31,134
Gross margin, as reported 17,191 14,018 13,353
Adjustments to gross margin:
Charges related to the flow-through of inventory step-up on business combinations - - 1,213
Adjusted gross margin 1 $17,191 $14,018 $14,566
Adjusted gross margin percentage 1 35% 34% 47%
1 Adjusted gross margin and adjusted gross margin percentage are non-GAAP measures. See "Non-GAAP Measures".
Last updated: Jun 1, 2021